Literature DB >> 1733767

Retroviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro.

M G Dunckley1, D R Love, K E Davies, F S Walsh, G E Morris, G Dickson.   

Abstract

We have demonstrated expression of a 6.3 kb Becker muscular dystrophy (BMD) human dystrophin cDNA following retroviral-mediated transduction of cultured myoblasts from the dystrophin-deficient mdx mouse. The truncated dystrophin protein was localised to the sarcolemma of differentiated myotubes by antibodies against the C-terminus of the molecule, and produced an identical immunostaining pattern to that observed in control myotubes expressing normal endogenous dystrophin. These results indicate that retroviral-mediated gene transfer may be useful for experimental in vivo studies on the complementation of dystrophin gene mutations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733767     DOI: 10.1016/0014-5793(92)80363-l

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

Review 1.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

2.  The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers.

Authors:  J Huard; W G Feero; S C Watkins; E P Hoffman; D J Rosenblatt; J C Glorioso
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 3.  Adenovirus-mediated gene transfer into striated muscles.

Authors:  G Acsadi; B Massie; A Jani
Journal:  J Mol Med (Berl)       Date:  1995-04       Impact factor: 4.599

4.  Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells.

Authors:  A Fassati; D J Wells; P A Sgro Serpente; F S Walsh; S C Brown; P N Strong; G Dickson
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

5.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

6.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

7.  Development of approaches to improve cell survival in myoblast transfer therapy.

Authors:  Z Qu; L Balkir; J C van Deutekom; P D Robbins; R Pruchnic; J Huard
Journal:  J Cell Biol       Date:  1998-09-07       Impact factor: 10.539

Review 8.  High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics.

Authors:  Thomas J J Gintjee; Alvin S H Magh; Carmen Bertoni
Journal:  Biology (Basel)       Date:  2014-11-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.